Suppr超能文献

一种用于蛋白质药物和生物标志物超灵敏和稳健靶向定量的捕集-微 LC-FAIMS/dCV-MS 策略。

A Trapping-Micro-LC-FAIMS/dCV-MS Strategy for Ultrasensitive and Robust Targeted Quantification of Protein Drugs and Biomarkers.

机构信息

The Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, New York 14214, United States.

Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Summit, New Jersey 07901, United States.

出版信息

Anal Chem. 2024 Aug 13;96(32):13140-13149. doi: 10.1021/acs.analchem.4c01888. Epub 2024 Jul 30.

Abstract

The sensitivity of LC-MS in quantifying target proteins in plasma/tissues is significantly hindered by coeluted matrix interferences. While antibody-based immuno-enrichment effectively reduces interferences, developing and optimizing antibodies are often time-consuming and costly. Here, by leveraging the orthogonal separation capability of Field Asymmetric Ion Mobility Spectrometry (FAIMS), we developed a FAIMS/differential-compensation-voltage (FAIMS/dCV) method for antibody-free, robust, and ultrasensitive quantification of target proteins directly from plasma/tissue digests. By comparing the intensity-CV profiles of the target vs coeluted endogenous interferences, the FAIMS/dCV approach identifies the optimal CV for quantification of each target protein, thus maximizing the signal-to-noise ratio (S/N). Compared to quantification without FAIMS, this technique dramatically reduces endogenous interferences, showing a median improvement of the S/N by 14.8-fold for the quantification of 17 representative protein drugs and biomarkers in plasma or tissues and a 5.2-fold median increase in S/N over conventional FAIMS approach, which uses the peak CV of each target. We also discovered that the established CV parameters remain consistent over months and are matrix-independent, affirming the robustness of the developed FAIMS/dCV method and the transferability of the method across matrices. The developed method was successfully demonstrated in three applications: the quantification of monoclonal antibodies with subng/mL LOQ in plasma, an investigation of the time courses of evolocumab and its target PCSK9 in a preclinical setting, and a clinical investigation of low abundance obesity-related biomarkers. This innovative and easy-to-use method has extensive potential in clinical and pharmaceutical research, particularly where sensitive and high-throughput quantification of protein drugs and biomarkers is required.

摘要

LC-MS 测定血浆/组织中目标蛋白的灵敏度受到共洗脱基质干扰的显著阻碍。尽管基于抗体的免疫富集可有效减少干扰,但开发和优化抗体通常耗时且昂贵。在这里,我们利用场不对称离子淌度光谱(FAIMS)的正交分离能力,开发了一种无抗体、稳健且超灵敏的 FAIMS/差分补偿电压(FAIMS/dCV)方法,可直接从血浆/组织消化物中定量测定目标蛋白。通过比较目标与共洗脱内源性干扰的强度-CV 曲线,FAIMS/dCV 方法确定了定量每个目标蛋白的最佳 CV,从而最大化信号与噪声比(S/N)。与无 FAIMS 的定量相比,该技术可显著减少内源性干扰,在定量测定 17 种代表性蛋白药物和生物标志物在血浆或组织中的 S/N 提高了中位数 14.8 倍,比使用每个目标峰 CV 的传统 FAIMS 方法提高了中位数 5.2 倍。我们还发现,建立的 CV 参数在数月内保持一致,且与基质无关,证实了所开发的 FAIMS/dCV 方法的稳健性和方法在不同基质间的可转移性。该方法在三个应用中得到了成功验证:在血浆中以亚纳克/毫升 LOQ 定量测定单克隆抗体,在临床前环境中研究依洛尤单抗及其靶标 PCSK9 的时间过程,以及临床研究低丰度肥胖相关生物标志物。这种创新且易于使用的方法在临床和药物研究中具有广泛的应用潜力,特别是在需要对蛋白药物和生物标志物进行敏感且高通量定量的情况下。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a9/11984221/20228b673551/nihms-2069766-f0001.jpg

相似文献

本文引用的文献

1
Chasing LDL cholesterol to the bottom - PCSK9 in perspective.将低密度脂蛋白胆固醇降至最低——PCSK9的前景展望
Nat Cardiovasc Res. 2022 Jun;1(6):554-561. doi: 10.1038/s44161-022-00085-x. Epub 2022 Jun 15.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验